Watson Seeks Co-Promotion Partner For Oxytrol In Primary Care Setting
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is seeking a partner with "strong relationships" with high-volume prescribers of overactive bladder therapies in the primary care market. Watson wants to retain Oxytrol's position in primary care despite the company's intention to shift its marketing focus to specialty care.
You may also be interested in...
Big Pharma Pushes Watson's Oxytrol To Specialty Area
Continued decline in sales of the overactive bladder patch reinforces Watson focus on the urologist specialty area; firm cites inadequate resources to compete with big pharma in the primary care market.
Big Pharma Pushes Watson's Oxytrol To Specialty Area
Continued decline in sales of the overactive bladder patch reinforces Watson focus on the urologist specialty area; firm cites inadequate resources to compete with big pharma in the primary care market.
Ventiv Dermatology Sales Force To Promote Ranbaxy’s Isotretinoin
The firms sign multi-year agreement to market Sotret. Ventiv says it has established a specialty dermatology sales force to promote the product.